Saturday 17 October 2026
Export VRAX’s income statement to Excel — free account
Virax Biolabs Group Limited
VRAX Healthcare Biotechnology
Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.
1.45
0.17
−10.49%
Follow VRAX
Virax Biolabs Group Limited (VRAX) P/E ratio
Virax Biolabs Group Limited has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2023 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| Mar 2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRTX Biorestorative Therapies, Inc. compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited | n/m |
| NTBLQ Notable Labs, Ltd. compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| CLSDQ Clearside Biomedical, Inc. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)